The prenatal and new-born genetic testing market is projected to exhibit substantial growth by 2027 driven by surging consumer awareness regarding the benefits of early detection and treatment of genetic disorders.

Moreover, increasing research focus on integrating advanced technologies to enhance testing outcomes is also propelling market development. For instance, an October 2020 study by researchers from the University of California showed promising results with the use of high-throughput DNA-sequencing technologies.

The researchers found that the technique called ???exome sequencing??? could enhance prenatal diagnosis as well as pregnancy outcomes in women with an abnormal prenatal ultrasound. The research, which was published in the New England Journal of Medicine (NEJM), found that, in 37 out of 127 cases, genetic diseases were the underlying cause of nonimmune hydrops fetalis (NIHF) - a life-threatening illness wherein there is abnormal fluid collection in the fetus.

Additionally, with the rising significance of prenatal and new-born genetic testing, more illnesses are being recommended for testing. This would allow early detection of genetic diseases and subsequently, prompt treatment for these illnesses.

For instance, in June 2021, it was announced that all babies born in North Carolina would be tested for spinal muscular atrophy (SMA) at birth under the North Carolina Newborn Screening Program. As part of the program, all newborns in the state are screened for numerous genetic diseases like cystic fibrosis and SMA, which is a common cause of death associated with genetic mutation among children, was added to this list of illnesses in May 2021.

Such early detection allows babies to commence treatment before they develop symptoms of a genetic disorder, which could give significantly better outcomes. Thus, prominent benefits of prenatal and new-born genetic testing is fueling its adoption worldwide, thereby bolstering market demand.

The prenatal and new-born genetic testing market has been segmented on the basis of technology, disease, end-use, and region. Based on technology, the market has been segregated into screening and diagnostic.

In 2020, the screening sub-segment held a significant share in the prenatal and new-born genetic testing market and is expected to be valued at around USD 6.1 billion by 2027. Rising demand for minimally-invasive prenatal testing across the globe owing to complications associated with invasive genetic testing is projected to support segmental adoption through the forecast period.

In terms of disease, the market has been divided into phenylketonuria, Down syndrome, sickle cell anemia, cystic fibrosis, and others. The phenylketonuria sub-segment accounted for a significant market share in 2020 and is anticipated to surpass a valuation of USD 1 billion by 2027. High prevalence of phenylketonuria, along with government initiatives to promote screening and diagnostics for early detection of phenylketonuria, is likely to fuel segmental growth over the analysis period.

Based on end-use, the market has further been segmented into maternity & specialty clinics, hospitals, and diagnostic centers. The maternity & specialty clinics sub-segment is anticipated to witness robust growth to reach a valuation of about USD 3.2 billion by 2027. Rising number of preterm births, high prenatal mortality rate, and increasing demand for prenatal care are speculated to facilitate segmental expansion over the following years.

On the regional spectrum, the Middle East & Africa prenatal and new-born genetic testing market valuation exceeded USD 80 million in 2020 and is projected to witness significant growth over 2021-2027. Augmenting prevalence of birth defects among newborns and growing frequency of chromosomal abnormalities in the fetus across the region are set to foster market outlook in the future.